Lack of group X secreted phospholipase A2 increases survival following pandemic H1N1 influenza infection

Virology

Volumn 454-455, Issue 1, 2014, Pages 78-92

  Kelvin, Alyson A ^a   Degousee, Norbert ^b   Banner, David ^c   Stefanski, Eva ^b   León, Alberto J ^c,d   Angoulvant, Denis ^e   Paquette, Stéphane G ^c,f   Huang, Stephen S H ^c,f   Danesh, Ali ^g   Robbins, Clinton S ^c   Noyan, Hossein ^c   Husain, Mansoor ^b,c   Lambeau, Gerard ^h   Gelb, Michael ⁱ   Kelvin, David J ^c,d,f,j   Rubin, Barry B ^b  

^a Immune Diagnostics and Research   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^e FHU SUPORT   (France)

^f UNIVERSITY OF TORONTO   (Canada)

^g BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^h INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j UNIVERSITY OF SASSARI   (Italy)

more..

Author keywords

H1N1 pandemic influenza; Host response; Inflammation; Influenza; Leukotrienes; Pathogenesis; Phospholipids; Prostaglandins

Indexed keywords

GROUP X SECRETED PHOSPHOLIPASE A2; LEUKOTRIENE B4; LIPOXIN A; PEPTIDOLEUKOTRIENE; PHOSPHOLIPASE A2; PROSTAGLANDIN D2; PROSTAGLANDIN E2; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DISEASE MODEL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE; GENE INDUCTION; GENE PRODUCT; GENE TARGETING; GX SPLA2 GENE; INFLUENZA A (H1N1); LUNG LAVAGE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PANDEMIC INFLUENZA; PATHOPHYSIOLOGY; PNEUMONIA; PRIORITY JOURNAL; SURVIVAL; T LYMPHOCYTE;

H1N1 PANDEMIC INFLUENZA; HOST RESPONSE; INFLAMMATION; INFLUENZA; LEUKOTRIENES; LIPOXIN A(4); PATHOGENESIS; PHOSPHOLIPIDS; PROSTAGLANDINS; SECRETED PHOSPHOLIPASE A(2);

ANIMALS; B-LYMPHOCYTES; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; GROUP X PHOSPHOLIPASES A2; INFLUENZA A VIRUS, H1N1 SUBTYPE; LUNG; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROARRAY ANALYSIS; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS; T-LYMPHOCYTES;

EID: 84896724052     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2014.01.030     Document Type: Article

References (74)

1. Arima M., Fukuda T. Prostaglandin D(2) and T(H)2 inflammation in the pathogenesis of bronchial asthma. Korean J. Intern. Med. 2011, 28:8-18.
2. Baillie J.K., Digard P. Influenza - time to target the host?. N. Engl. J. Med. 2013, 369:191-193. 10.1056/NEJMcibr1304414.
3. Bermejo-Martin J.F., Ortiz de L.R., Pumarola T., Rello J., Almansa R., Ramirez P., Martin-Loeches I., Varillas D., Gallegos M.C., Seron C., Micheloud D., Gomez J.M., Tenorio-Abreu A., Ramos M.J., Molina M.L., Huidobro S., Sanchez E., Gordon M., Fernandez V., Del C.A., Marcos M.A., Villanueva B., Lopez C.J., Rodriguez-Dominguez M., Galan J.C., Canton R., Lietor A., Rojo S., Eiros J.M., Hinojosa C., Gonzalez I., Torner N., Banner D., Leon A., Cuesta P., Rowe T., Kelvin D.J. Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza. Crit. Care 2009, 13:R201. (doi:cc8208 [pii];10.1186/cc8208 [doi]).
4. Bermejo-Martin J.F., Martin-Loeches I., Rello J., Anton A., Almansa R., Xu L., Lopez-Campos G., Pumarola T., Ran L., Ramirez P., Banner D., Ng D.C., Socias L., Loza A., Andaluz D., Maravi E., Gomez-Sanchez M.J., Gordon M., Gallegos M.C., Fernandez V., Aldunate S., Leon C., Merino P., Blanco J., Martin-Sanchez F., Rico L., Varillas D., Iglesias V., Marcos M.A., Gandia F., Bobillo F., Nogueira B., Rojo S., Resino S., Castro C., Ortiz de L.R., Kelvin D. Host adaptive immunity deficiency in severe pandemic influenza. Crit. Care 2010, 14:R167. (doi:cc9259 [pii];10.1186/cc9259 [doi]).
5. Bhavsar P.K., Levy B.D., Hew M.J., Pfeffer M.A., Kazani S., Israel E., Chung K.F. Corticosteroid suppression of lipoxin A4 and leukotriene B4 from alveolar macrophages in severe asthma 12. Respir. Res. 2010, 11:71. (doi:1465-9921-11-71 [pii];10.1186/1465-9921-11-71 [doi]).
6. Cameron C.M., Cameron M.J., Bermejo-Martin J.F., Ran L., Xu L., Turner P.V., Ran R., Danesh A., Fang Y., Chan P.K., Mytle N., Sullivan T.J., Collins T.L., Johnson M.G., Medina J.C., Rowe T., Kelvin D.J. Gene expression analysis of host innate immune responses during Lethal H5N1 infection in ferrets. J. Virol. 2008, 82:11308-11317. (doi:JVI.00691-08 [pii];10.1128/JVI.00691-08 [doi]).
7. Cameron M.J., Ran L., Xu L., Danesh A., Bermejo-Martin J.F., Cameron C.M., Muller M.P., Gold W.L., Richardson S.E., Poutanen S.M., Willey B.M., Devries M.E., Fang Y., Seneviratne C., Bosinger S.E., Persad D., Wilkinson P., Greller L.D., Somogyi R., Humar A., Keshavjee S., Louie M., Loeb M.B., Brunton J., McGeer A.J., Kelvin D.J. Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J. Virol. 2007, 81:8692-8706. (doi:JVI.00527-07 [pii];10.1128/JVI.00527-07 [doi]).
8. Cameron M.J., Kelvin A.A., Leon A.J., Cameron C.M., Ran L., Xu L., Chu Y.K., Danesh A., Fang Y., Li Q., Anderson A., Couch R.C., Paquette S.G., Fomukong N.G., Kistner O., Lauchart M., Rowe T., Harrod K.S., Jonsson C.B., Kelvin D.J. Lack of innate interferon responses during SARS coronavirus infection in a vaccination and reinfection Ferret Model2. PLoS One 2012, 7:e45842. (doi:10.1371/journal.pone.0045842 [doi];PONE-D-12-09714 [pii]).
9. Crooks S.W., Stockley R.A. Leukotriene B42. Int. J. Biochem. Cell Biol. 1998, 30:173-178. (doi:S1357-2725(97)00123-4 [pii]), (doi:S1357-2725(97)00123-4 [pii]).
10. 2 group X enhances anti-inflammatory responses, promotes lipid accumulation, and contributes to aberrant lung pathology. J. Biol. Chem. 2008, 283:21640-21648. (doi:M710584200 [pii];10.1074/jbc.M710584200 [doi]).
11. 2 alveolar activity in infants with ARDS. PLoS One 2012, 7:e47066. (doi:10.1371/journal.pone.0047066 [doi];PONE-D-12-14582 [pii]).
12. 2 expression in interleukin-1b stimulated rat neonatal cardiomyocytes. J. Biol. Chem. 2001, 276:43842-43849.
13. 2s in human neutrophils: role in eicosanoid production and gram-negative bacterial phospholipid hydrolysis. J. Biol. Chem. 2002, 277:5061-5073.
14. Degousee N., Martindale J., Stefanski E., Cieslak M., Lindsay T.F., Fish J.E., Marsden P.A., Thuerauf D.J., Glembotski C.C., Rubin B.B. MAP kinase kinase 6-p38 MAP kinase signaling cascade regulates cyclooxygenase-2 expression in cardiac myocytes in vitro and in vivo. Circ. Res. 2003, 92:757-764.
15. 2 biosynthesis by cardiomyocytes. J. Biol. Chem. 2006, 281:16443-16452.
16. Degousee N., Fazel S., Angoulvant D., Stefanski E., Pawelzik S.C., Korotkova M., Arab S., Liu P., Lindsay T.F., Zhuo S., Butany J., Li R.K., Audoly L., Schmidt R., Angioni C., Geisslinger G., Jakobsson P.J., Rubin B.B. Microsomal prostaglandin E2 synthase-1 deletion leads to adverse left ventricular remodeling after myocardial infarction. Circulation 2008, 117:1701-1710.
17. Del P.A., Shao W.H., Mitola S., Santoro G., Sozzani S., Haribabu B. Regulation of dendritic cell migration and adaptive immune response by leukotriene B4 receptors: a role for LTB4 in up-regulation of CCR7 expression and function1. Blood 2007, 109:626-631. (doi:blood-2006-02-003665 [pii];10.1182/blood-2006-02-003665 [doi]).
18. 2. J. Biol. Chem. 1994, 269:13057-13060.
19. de Jong M.D., Simmons C.P., Thanh T.T., Hien V.M., Smith G.J., Chau T.N., Hoang D.M., Chau N.V., Khanh T.H., Dong V.C., Qui P.T., Cam B.V., Ha d.Q., Guan Y., Peiris J.S., Chinh N.T., Hien T.T., Farrar J. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med. 2006, 12:1203-1207. (doi:nm1477 [pii];10.1038/nm1477 [doi]).
20. 2 is released during sperm acrosome reaction and controls fertility outcome in mice. J. Clin. Invest. 2010, 120:1415-1428. (doi:40494 [pii];10.1172/JCI40494 [doi]).
21. Fang Y., Banner D., Kelvin A.A., Huang S.S., Paige C.J., Corfe S.A., Kane K.P., Bleackley R.C., Rowe T., Leon A.J., Kelvin D.J. Seasonal H1N1 infection induces cross protective pandemic H1N1 immunity through a CD8 independent, B cell dependent mechanism. J. Virol. 2011, 86:2229-2238. (doi:JVI.05540-11 [pii];10.1128/JVI.05540-11 [doi]).
22. 2 and phagocyte NADPH oxidase in digestion of phospholipids of Staphylococcus aureus ingested by human neutrophils. J. Immunol. 2005, 175:4653-4661.
23. 2. J. Lipid Res. 2005, 46:1248-1256. (doi:M400499-JLR200 [pii];10.1194/jlr.M400499-JLR200 [doi]).
24. Gao R., Cao B., Hu Y., Feng Z., Wang D., Hu W., Chen J., Jie Z., Qiu H., Xu K., Xu X., Lu H., Zhu W., Gao Z., Xiang N., Shen Y., He Z., Gu Y., Zhang Z., Yang Y., Zhao X., Zhou L., Li X., Zou S., Zhang Y., Li X., Yang L., Guo J., Dong J., Li Q., Dong L., Zhu Y., Bai T., Wang S., Hao P., Yang W., Zhang Y., Han J., Yu H., Li D., Gao G.F., Wu G., Wang Y., Yuan Z., Shu Y. Human infection with a novel avian-origin influenza A (H7N9) virus. N. Engl. J. Med. 2013, 368:1888-1897. (doi:10.1056/NEJMoa1304459 [doi]).
25. Gaudreault E., Gosselin J. Leukotriene B4-mediated release of antimicrobial peptides against cytomegalovirus is BLT1 dependent. Viral Immunol. 2007, 20:407-420. (doi:10.1089/vim.2006.0099 [doi]).
26. Gaudreault E., Gosselin J. Leukotriene B4 induces release of antimicrobial peptides in lungs of virally infected mice. J. Immunol. 2008, 180:6211-6221. (doi:180/9/6211 [pii]).
27. 2 in mammalian brain and neural cells: roles in functions and dysfunctions4. Mol. Neurobiol. 2010, 41:274-289. (doi:10.1007/s12035-010-8108-6 [doi]).
28. Groom J.R., Luster A.D. CXCR3 ligands: redundant, collaborative and antagonistic functions4. Immunol. Cell Biol. 2011, 89:207-215. (doi:icb2010158 [pii];10.1038/icb.2010.158 [doi]).
29. Guan Y., Farooqui A., Zhu H., Dong W., Wang J., Kelvin D.J. H7N9 incident, immune status, the elderly and a warning of an influenza pandemic. J. Infect. Dev. Ctries. 2013, 7:302-307.
30. + channel. Evidence that gp91-phox functions as an essential part of the channel. J. Biol. Chem. 1995, 270:5909-5916.
31. 2 in allergen-induced airway inflammation and remodeling in a mouse asthma model. J. Exp. Med. 2007, 204:865-877.
32. 2 inhibitor. J. Biol. Chem. 2011, 286:28049-28055. (doi:M111.235812 [pii];10.1074/jbc.M111.235812 [doi]).
33. Hicks A., Monkarsh S.P., Hoffman A.F., Goodnow R. Leukotriene B4 receptor antagonists as therapeutics for inflammatory disease: preclinical and clinical developments. Expert Opin. Investig. Drugs 2007, 16:1909-1920. (doi:10.1517/13543784.16.12.1909 [doi]).
34. Huang S.S., Banner D., Fang Y., Ng D.C., Kanagasabai T., Kelvin D.J., Kelvin A.A. Comparative analyses of pandemic H1N1 and seasonal H1N1, H3N2, and influenza B infections depict distinct clinical pictures in ferrets. PLoS One 2011, 6:e27512. (doi:10.1371/journal.pone.0027512 [doi];PONE-D-11-09202 [pii]).
35. Huang S.S., Banner D., Degousee N., Leon A.J., Xu L., Paquette S.G., Kanagasabai T., Fang Y., Rubino S., Rubin B., Kelvin D.J., Kelvin A.A. Differential pathological and immune responses in newly weaned ferrets are associated with mild clinical outcome of pandemic 2009 H1N1 Infection1. J. Virol. 2012, 86:13187-13701. (doi:JVI.01456-12 [pii];10.1128/JVI.01456-12 [doi]).
36. Huang d.W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009, 4:44-57. (doi:nprot.2008.211 [pii];10.1038/nprot.2008.211 [doi]).
37. Influenza Activity - United States and Worldwide, June 13-September 25, 2010. Morbidity and Mortality Weekly Report (MMWR). Vol. 59, pp. 1270-1273. (doi:mm5939a3 [pii]).
38. 2 on human endothelial cell function. FASEB J. 2006, 20:2547-2549. (doi:fj.06-6018fje [pii];10.1096/fj.06-6018fje [doi]).
39. 2 gene in inbred mouse strains. J. Biol. Chem. 1995, 270:22378-22385.
40. 2. J. Virol. 2007, 81:1444-1450. (doi:JVI.01790-06 [pii];10.1128/JVI.01790-06 [doi]).
41. Kudo I., Murakami M. Diverse functional coupling of prostanoid biosynthetic enzymes in various cell types. Adv. Exp. Med. Biol. 1999, 469:29-35.
42. Leon A.J., Banner D., Xu L., Ran L., Peng Z., Yi K., Chen C., Xu F., Huang J., Zhao Z., Lin Z., Huang S.H., Fang Y., Kelvin A.A., Ross T.M., Farooqui A., Kelvin D.J. Sequencing, annotation and characterization of the influenza ferret infectome1. J. Virol. 2012, 87:1957-1966. (doi:JVI.02476-12 [pii];10.1128/JVI.02476-12 [doi]).
43. Lu Z., Serghides L., Patel S.N., Degousee N., Rubin B.B., Krishnegowda G., Gowda D.C., Karin M., Kain K.C. Disruption of JNK2 decreases the cytokine response to Plasmodium falciparum glycosylphosphatidylinositol in vitro and confers protection in a cerebral malaria model. J. Immunol. 2006, 177:6344-6352.
44. 2 in arachidonic acid release from human neutrophils. J. Immunol. 2000, 164:2084-2091.
45. 2 enzymes in lungs of humans with pneumonia and their potential prostaglandin-synthetic function in human lung-derived cells. Biochem. J. 2005, 387:27-38.
46. Matsuoka T., Hirata M., Tanaka H., Takahashi Y., Murata T., Kabashima K., Sugimoto Y., Kobayashi T., Ushikubi F., Aze Y., Eguchi N., Urade Y., Yoshida N., Kimura K., Mizoguchi A., Honda Y., Nagai H., Narumiya S. Prostaglandin D2 as a mediator of allergic asthma5. Science 2000, 287:2013-2017. (doi:8366 [pii]).
47. Mazur I., Wurzer W.J., Ehrhardt C., Pleschka S., Puthavathana P., Silberzahn T., Wolff T., Planz O., Ludwig S. Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF-kappaB-inhibiting activity. Cell Microbiol. 2007, 9:1683-1694. (doi:CMI902 [pii];10.1111/j.1462-5822.2007.00902.x [doi]).
48. 2 prevents adenoviral infection in mammalian cells. Biochem. J. 2006, 393:97-106. (doi:BJ20050781 [pii];10.1042/BJ20050781 [doi]).
49. Morita M., Kuba K., Ichikawa A., Nakayama M., Katahira J., Iwamoto R., Watanebe T., Sakabe S., Daidoji T., Nakamura S., Kadowaki A., Ohto T., Nakanishi H., Taguchi R., Nakaya T., Murakami M., Yoneda Y., Arai H., Kawaoka Y., Penninger J.M., Arita M., Imai Y. The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza. Cell 2013, 153:112-125. (doi:S0092-8674(13)00216-X [pii];10.1016/j.cell.2013.02.027 [doi]).
50. Murakami M., Kambe T., Shimbara S., Higashino K., Hanasaki K., Arita H., Horiguchi M., Arita M., Arai H., Inoue K., Kudo I. Different functional aspects of the group II subfamily (Types IIA and V) and type X secretory phospholipase A(2)s in regulating arachidonic acid release and prostaglandin generation. Implications of cyclooxygenase-2 induction and phospholipid scramblase-mediated cellular membrane perturbation57. J. Biol. Chem. 1999, 274:31435-31444.
51. Murakami M., Taketomi Y., Miki Y., Sato H., Hirabayashi T., Yamamoto K. Recent progress in phospholipase A(2) research: from cells to animals to humans. Prog. Lipid Res. 2011, 50:152-192. (doi:S0163-7827(10)00065-2 [pii];10.1016/j.plipres.2010.12.001 [doi]).
52. Muthuswamy R., Mueller-Berghaus J., Haberkorn U., Reinhart T.A., Schadendorf D., Kalinski P. PGE(2) transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells11. Blood 2010, 116:1454-1459. (doi:blood-2009-12-258038 [pii];10.1182/blood-2009-12-258038 [doi]).
53. Myers R.C., King R.G., Carter R.H., Justement L.B. Lymphotoxin alpha(1) beta(2) expression on B cells is required for follicular dendritic cell activation during the germinal center response1. Eur. J. Immunol. 2012, 43:348-359. ([doi]). 10.1002/eji.201242471.
54. Napolitani G., Acosta-Rodriguez E.V., Lanzavecchia A., Sallusto F. Prostaglandin E2 enhances Th17 responses via modulation of IL-17 and IFN-gamma production by memory CD4+ T cells3. Eur. J. Immunol. 2009, 39:1301-1312. ([doi]). 10.1002/eji.200838969.
55. 2 in mice leads to neonatal lethality because of lung dysfunction. J. Biol. Chem. 2006, 281:36420-36433. (doi:M607975200 [pii];10.1074/jbc.M607975200 [doi]).
56. Paquette S.G., Banner D., Zhao Z., Fang Y., Huang S.S., Leomicronn A.J., Ng D.C., Almansa R., Martin-Loeches I., Ramirez P., Socias L., Loza A., Blanco J., Sansonetti P., Rello J., Andaluz D., Shum B., Rubino S., de Lejarazu R.O., Tran D., Delogu G., Fadda G., Krajden S., Rubin B.B., Bermejo-Martin J.F., Kelvin A.A., Kelvin D.J. Interleukin-6 is a potential biomarker for severe pandemic H1N1 influenza A infection2. PLoS One 2012, 7:e38214. (doi:10.1371/journal.pone.0038214 [doi];PONE-D-11-22886 [pii]).
57. Paquette S.G., Banner D., Chi T.B., le A.J., Leomicronn L., Xu L., Ran S.S., Huang A., Farooqui D.J., Kelvin, Kelvin A.A. Pandemic H1N1 influenza A directly induces a robust and acute inflammatory gene signature in primary human bronchial epithelial cells downstream of membrane fusion. Virology 2014, 448:91-103. (doi:S0042-6822(13)00555-2 [pii];10.1016/j.virol.2013.09.022 [doi]).
58. Rowe T., Banner D., Farooqui A., Ng D.C.K., Kelvin A.A., Rubino S., Huang S.S.H., Fang Y., Kelvin D.J. In vivo ribavirin activity against severe pandemic H1N1 influenza A/Mexico/4108/2009. J. Gen. Virol. 2010.
59. Rowe T., Leon A.J., Crevar C.J., Carter D.M., Xu L., Ran L., Fang Y., Cameron C.M., Cameron M.J., Banner D., Ng D.C., Ran R., Weirback H.K., Wiley C.A., Kelvin D.J., Ross T.M. Modeling host responses in ferrets during A/California/07/2009 influenza infection. Virology 2010, 401:257-265. (doi:S0042-6822(10)00129-7 [pii];10.1016/j.virol.2010.02.020 [doi]).
60. 2-a does not regulate neutrophil NADPH oxidase activity. J. Biol. Chem. 2005, 280:7519-7529.
61. Rusinova I., Forster S., Yu S., Kannan A., Masse M., Cumming H., Chapman R., Hertzog P.J. INTERFEROME v2.0: an updated database of annotated interferon-regulated genes1. Nucl. Acids Res. 2012, 41:D1040-D1046. (doi:gks1215 [pii];10.1093/nar/gks1215 [doi]).
62. Sadik C.D., Luster A.D. Lipid-cytokine-chemokine cascades orchestrate leukocyte recruitment in inflammation2. J. Leukoc. Biol. 2012, 91:207-215. (doi:jlb.0811402 [pii];10.1189/jlb.0811402 [doi]).
63. Saez de G.J., Barrio L., Mellado M., Carrasco Y.R. CXCL13/CXCR5 signaling enhances BCR-triggered B-cell activation by shaping cell dynamics1. Blood 2011, 118:1560-1569. (doi:blood-2011-01-332106 [pii];10.1182/blood-2011-01-332106 [doi]).
64. Santone D.J., Shahani R., Rubin B.B., Romaschin A.D., Lindsay T.F. Mast cell stabilization improves cardiac contractile function following hemorrhagic shock and resuscitation. Am. J. Physiol. Heart Circ. Physiol. 2008, 294:H2456-H2464.
65. Schultz-Cherry S., Jones J.C. Influenza vaccines: the good, the bad, and the eggs. Adv. Virus Res. 2010, 77:63-84. (doi:B978-0-12-385034-8.00003-X [pii];10.1016/B978-0-12-385034-8.00003-X [doi]).
66. 2 enhances TLR4 signaling in macrophages1. J. Immunol. 2011, 187:482-489. (doi:jimmunol.1003552 [pii];10.4049/jimmunol.1003552 [doi]).
67. Stephenson A.H., Lonigro A.J., Hyers T.M., Webster R.O., Fowler A.A. Increased concentrations of leukotrienes in bronchoalveolar lavage fluid of patients with ARDS or at risk for ARDS. Am. Rev. Respir. Dis. 1988, 138:714-719.
68. Truchetet M.E., Allanore Y., Montanari E., Chizzolini C., Brembilla N.C. Prostaglandin I(2) analogues enhance already exuberant Th17 cell responses in systemic sclerosis3. Ann. Rheum. Dis. 2012, 71:2044-2050. (doi:annrheumdis-2012-201400 [pii];10.1136/annrheumdis-2012-201400 [doi].).
69. Update: Influenza Activity - United States, 2009-10 season. Morbidity and Mortality Weekly Report (MMWR). Vol. 59, pp. 901-908. (doi:mm5929a2 [pii]).
70. Van Elssen C.H., Vanderlocht J., Oth T., Senden-Gijsbers B.L., Germeraad W.T., Bos G.M. Inflammation-restraining effects of prostaglandin E2 on natural killer-dendritic cell (NK-DC) interaction are imprinted during DC maturation1. Blood 2011, 118:2473-2482. (doi:blood-2010-09-307835 [pii];10.1182/blood-2010-09-307835 [doi]).
71. Widegren H., Andersson M., Borgeat P., Flamand L., Johnston S., Greiff L. LTB4 increases nasal neutrophil activity and conditions neutrophils to exert antiviral effects2. Respir. Med. doi:S0954-6111(10)00566-4 [pii];10.1016/j.rmed.2010.12.021 [doi] 2011, 105:997-1006.
72. World Health Organization, 2012. Global Influenza Programme. (Ref Type: Online Source).
73. Zhang P., Summer W.R., Bagby G.J., Nelson S. Innate immunity and pulmonary host defense. Immunol. Rev. 2000, 173:39-51.
74. Zhao J., Zhao J., Legge K., Perlman S. Age-related increases in PGD(2) expression impair respiratory DC migration, resulting in diminished T cell responses upon respiratory virus infection in mice1. J. Clin. Invest. 2011, 121:4921-4930. (doi:59777 [pii];10.1172/JCI59777 [doi]).